Navigation Links
Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
Date:9/1/2010

SANTA MONICA, Calif., Sept. 1 /PRNewswire/ -- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

"Despite the availability of several therapies for the treatment of metastatic renal cancer, there is a significant need for new renal cancer therapies," said Leonard Reyno, M.D., Senior Vice President and Chief Medical Officer at Agensys. "We believe AGS-16M8F, which is an ADC designed to deliver the potent cytotoxic agent MMAF directly to tumor cells, has the potential to provide a new therapeutic option for this disease."

The single-agent, Phase I, open-label, dose-escalation study will evaluate the safety and tolerability of AGS-16M8F in patients with renal cancer and identify the maximum tolerated dose. Secondary objectives include assessing the pharmacokinetics and antitumor activity of AGS-16M8F and identifying a recommended dose and regimen for future clinical trials. The study is designed to enroll approximately 50 patients at multiple centers in the United States.

Dr. David Stover, Vice President and Head of Research at Agensys, noted that AGS-16M8F is an ADC composed of a fully human monoclonal antibody directed to ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), a novel cancer target identified by Agensys to be upregulated in the majority of renal cancers.

The antibody is attached to a highly potent, synthetic agent, monomethyl auristatin F (MMAF), via a non-cleavable linker using Seattle Genetics' proprietary technology. The novel linker system is designed to be stable in the bloodstream and release the potent cell-killing agent once inside antigen-expressing cancer cells. This approach is i
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UCI Medical Affiliates, Inc. Reports Third Quarter Results for Fiscal Year 2010
2. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
3. US Oncology Ranks 2nd in Affiliate Member Accruals for Radiation Therapy Oncology Group
4. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2009 Third Quarter Results
5. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
6. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
7. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
8. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
11. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...
... economic slowdown, America,s pharmaceutical research and biotechnology companies ... the research and development of new life-changing medicines ... billion from 2007, according to analyses by the ... Burrill & Company. PhRMA-member companies alone invested ...
Cached Medicine Technology:Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Foundation) introduced its new store run by GoodThreads. The store can be accessed ... products and designs, many of which are customizable. The best part: whenever a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Australia, April 20 Progen Pharmaceuticals Limited (ASX: PGL; ... that shows its epigenetic technology successfully inhibits tumor ... Progen,s collaborators at the 100th Annual American Association ... was effective in ,switching on, important anti-cancer genes ...
... with the power and influence to improve the healthcare ... to reform the nation,s healthcare system dominate Modern ... Healthcare for 2009. Among those making the list are ... Services Department; Nancy-Ann DeParle, director of the newly created ...
... - A national team of researchers led by Mayo Clinic ... more likely to have similar DNA changes or variants in ... have the cancer. , The findings, being presented at the ... an independent validation of an earlier European study that found ...
... Southern California have identified a new drug compound that ... without the negative side effects typically associated with Cox-2 ... to have a strong anti-tumor effect while also attacking ... tumor growth, according to data presented at the AACR ...
... Universal Health Realty Income Trust (NYSE: UHT ) ... C. Stein as a Trustee. Mr. Stein becomes the seventh ... Trustee. Mr. Stein, 50, is currently president and ... real estate company specializing in the acquisition, development, leasing and ...
... to Provide Free Counseling to Military Members, Veterans, and ... is honoring National Volunteer Week (April 19-25, 2009) with ... professionals to join the Give an Hour(TM) network to ... Hour(TM) is a nonprofit organization that has created a ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:Health Reformers Dominate Magazine's List of the Top 25 Women in Healthcare 2Health News:Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:Give an Hour(TM) Honors National Volunteer Week with Call to Service 2
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. Two 25G (.50mm) parallel ...
... product designed for LASIK surgery and ... to irrigate the corneal interface and/or ... insertion under the flap and helps ... provide multi-directional irrigation. 25G x 7/8in ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
Medicine Products: